Our study supports the efficacy of GLP-1 RAs in reducing cardiovascular events among individuals with concurrent type 2 diabetes and AKD, highlighting their role in the complex management of these comorbid conditions. The gene discussed is GCG; the disease is type 2 diabetes mellitus.